Worth Venture Partners’s CTI BioPharma Corp. (DE) Common Stock CTIC Stock Holding History

Worth Venture Partners’s Portfolio CTIC Stock Details CTIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-516,589	Closed	-$2.17M	–	214
2023 Q1	$2.17M	Buy	516,589 +151,594	+42%	+$787K	1.06%	23
2022 Q4	$2.19M	Buy	+364,995	New	+$1.99M	1.29%	26

Other funds holding CTIC

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Worth Venture Partners's CTIC Position: Q2 2023 in Review

Worth Venture Partners sold out of CTI BioPharma Corp. (DE) Common Stock (CTIC) in Q2 2023, closing a stake of 516,589 shares — an estimated $2.17M sold.

Worth Venture Partners first reported a position in CTIC in Q4 2022 and held it in 2 quarters. The position peaked at $2.19M in Q4 2022. 2 funds tracked by Wall St. Rank hold CTIC as of Q2 2023.

Worth Venture Partners reported no remaining CTI BioPharma Corp. (DE) Common Stock position as of Q2 2023 after selling out during the quarter.
Worth Venture Partners sold 516,589 CTI BioPharma Corp. (DE) Common Stock shares in Q2 2023, an estimated $2.17M.
Worth Venture Partners first reported a position in CTI BioPharma Corp. (DE) Common Stock in Q4 2022 and held it in 2 quarters.
Worth Venture Partners's CTI BioPharma Corp. (DE) Common Stock position peaked at $2.19M in Q4 2022.
2 funds tracked by Wall St. Rank held CTI BioPharma Corp. (DE) Common Stock as of Q2 2023.

Based on Worth Venture Partners's 13F filing for Q2 2023, filed 14 Aug 2023.